1. Home
  2. KRNY vs EOLS Comparison

KRNY vs EOLS Comparison

Compare KRNY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRNY
  • EOLS
  • Stock Information
  • Founded
  • KRNY 1884
  • EOLS 2012
  • Country
  • KRNY United States
  • EOLS United States
  • Employees
  • KRNY N/A
  • EOLS N/A
  • Industry
  • KRNY Savings Institutions
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • KRNY Finance
  • EOLS Health Care
  • Exchange
  • KRNY Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • KRNY 420.7M
  • EOLS 493.5M
  • IPO Year
  • KRNY 2005
  • EOLS 2018
  • Fundamental
  • Price
  • KRNY $6.74
  • EOLS $6.42
  • Analyst Decision
  • KRNY Buy
  • EOLS Strong Buy
  • Analyst Count
  • KRNY 2
  • EOLS 5
  • Target Price
  • KRNY $7.75
  • EOLS $21.25
  • AVG Volume (30 Days)
  • KRNY 376.6K
  • EOLS 887.6K
  • Earning Date
  • KRNY 10-23-2025
  • EOLS 11-05-2025
  • Dividend Yield
  • KRNY 6.54%
  • EOLS N/A
  • EPS Growth
  • KRNY N/A
  • EOLS N/A
  • EPS
  • KRNY 0.42
  • EOLS N/A
  • Revenue
  • KRNY $151,629,000.00
  • EOLS $277,941,000.00
  • Revenue This Year
  • KRNY $14.22
  • EOLS $13.68
  • Revenue Next Year
  • KRNY N/A
  • EOLS $27.96
  • P/E Ratio
  • KRNY $16.13
  • EOLS N/A
  • Revenue Growth
  • KRNY 12.84
  • EOLS 17.15
  • 52 Week Low
  • KRNY $5.45
  • EOLS $5.71
  • 52 Week High
  • KRNY $8.59
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • KRNY 61.66
  • EOLS 32.00
  • Support Level
  • KRNY $6.35
  • EOLS $7.19
  • Resistance Level
  • KRNY $6.72
  • EOLS $6.77
  • Average True Range (ATR)
  • KRNY 0.18
  • EOLS 0.30
  • MACD
  • KRNY -0.01
  • EOLS -0.07
  • Stochastic Oscillator
  • KRNY 73.58
  • EOLS 1.85

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: